CN117137965A - Application of rhizoma corydalis extract in preparation of medicine for treating atopic dermatitis - Google Patents
Application of rhizoma corydalis extract in preparation of medicine for treating atopic dermatitis Download PDFInfo
- Publication number
- CN117137965A CN117137965A CN202311315432.7A CN202311315432A CN117137965A CN 117137965 A CN117137965 A CN 117137965A CN 202311315432 A CN202311315432 A CN 202311315432A CN 117137965 A CN117137965 A CN 117137965A
- Authority
- CN
- China
- Prior art keywords
- medicament
- atopic dermatitis
- extract
- skin
- rhizoma corydalis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000218176 Corydalis Species 0.000 title claims abstract description 49
- 239000003814 drug Substances 0.000 title claims abstract description 49
- 206010012438 Dermatitis atopic Diseases 0.000 title claims abstract description 28
- 201000008937 atopic dermatitis Diseases 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims description 10
- 210000003491 skin Anatomy 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 230000006378 damage Effects 0.000 claims description 9
- 208000003251 Pruritus Diseases 0.000 claims description 8
- 230000037365 barrier function of the epidermis Effects 0.000 claims description 8
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 3
- 210000002615 epidermis Anatomy 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 24
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 17
- 229960002882 calcipotriol Drugs 0.000 description 16
- 229940079593 drug Drugs 0.000 description 15
- 210000005069 ears Anatomy 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 8
- 238000006748 scratching Methods 0.000 description 5
- 230000002393 scratching effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- AEQDJSLRWYMAQI-UHFFFAOYSA-N Tetrahydropalmatine Natural products C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- AEQDJSLRWYMAQI-KRWDZBQOSA-N tetrahydropalmatine Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-KRWDZBQOSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000013585 weight reducing agent Substances 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides application of corydalis tuber extract in preparing medicament for treating atopic dermatitis, and the invention determines that the corydalis tuber extract has definite therapeutic effect on improving atopic dermatitis symptoms through research, and toxic and side effects are smaller than those of the clinical common glucocorticoid medicaments.
Description
Technical Field
The invention belongs to the field of preparation of anti-atopic dermatitis medicines, and relates to application of a corydalis tuber extract in preparation of a medicine for treating atopic dermatitis.
Background
Yan Hu is indicated for angina pectoris and arrhythmia due to its actions of activating blood and promoting qi circulation, especially good at relieving pain, and all pain belongs to the blood stasis and qi stagnation. Can be used for treating headache, menstrual pain, and pain of gastrointestinal tract, liver and gallbladder, and has analgesic effect higher than common antipyretic analgesic. The medicine has analgesic effect after 15 minutes of administration, is maintained for 2-5 hours, has good analgesic effect on dull pain caused by gastrointestinal tract system, and is more suitable for insomnia, especially insomnia caused by pain. The product can be taken after being ground into powder and swallowed, and is mostly prepared into traditional Chinese medicine such as rhizoma corydalis pain relieving tablets in modern times, has the effects of regulating qi, activating blood and relieving pain, and is commonly used for treating abdominal pain, stomachache, hypochondriac pain and headache during menstruation.
Atopic dermatitis, also known as atopic eczema, is a chronic, recurrent, inflammatory skin disease characterized clinically by dry skin, severe itching and eczematoid rash. Frequently, the infant starts to develop diseases, repeatedly attacks, and severe night itch affects sleeping and daily life.
The etiology of the disease is currently unknown and may be related to genetic, immunological abnormalities, environmental factors, and skin barrier dysfunction. Atopic dermatitis is characterized in that on the basis of genetic factors, allergens enter a human body or microorganisms to obtain a skin definite value (such as staphylococcus aureus and malassezia), so that skin immune abnormal reaction and inflammation are caused, skin rash and itching are caused, and bad stimulus such as scratching, excessive washing and the like can further aggravate skin.
The therapeutic principle of atopic dermatitis is to restore the normal barrier function of the skin, relieve or eliminate clinical symptoms, search for and eliminate inducing and aggravating factors, reduce and prevent recurrence, and improve the quality of life of patients. At present, external medicines mainly comprising glucocorticoid and antibiotics are mainly adopted as treatment means. For severe patients, antihistamines, antibiotics, antiviral drugs, and immunosuppressants can be administered orally. In addition, glycyrrhizic acid preparation, calcium preparation and probiotics can be used as adjuvant therapy. However, the existing medicines can only relieve symptoms, have large side effects and cannot be used for a long time. There is no medicine for completely curing atopic dermatitis, and development of a novel safe and effective medicine for treating atopic dermatitis is urgently needed.
Currently, no report on the relevant application of corydalis tuber extract as an anti-atopic dermatitis drug is seen.
Disclosure of Invention
In order to overcome the defects of the prior art, the invention aims to provide the application of the corydalis tuber extract in preparing the medicine for treating the atopic dermatitis.
The invention is realized by the following technical scheme:
application of rhizoma corydalis extract in preparing medicine for treating atopic dermatitis is provided.
Preferably, the drug is a drug that inhibits damage to the epidermal barrier of the skin.
Preferably, the drug is a drug that inhibits skin scaling.
Preferably, the drug is a drug for inhibiting the release of the skin itch medium.
Preferably, the drug is a drug for inhibiting the release of skin epidermal inflammatory factors.
Preferably, the preparation method of the corydalis tuber extract comprises the following steps: pulverizing rhizoma corydalis, adding ethanol solution, heating under reflux, collecting extractive solution, filtering, and concentrating the filtrate.
A medicament for treating atopic dermatitis, the medicament comprising a corydalis tuber extract.
Preferably, the medicament is in the form of gel, ointment, cream, powder, aqua or lotion.
Further, the concentration of the corydalis tuber extract in the medicine is 0.1-0.4g/mL.
Compared with the prior art, the invention has the following beneficial effects:
the invention discloses a corydalis tuber extract which has definite treatment effect on improving atopic dermatitis symptoms, and has less toxic and side effects than the clinical common glucocorticoid medicaments. According to the invention, the treatment effect of the medicine on the atopic dermatitis is evaluated by comparing the ear scratching times, the weight reduction degree, the skin barrier damage condition and the ear thickness increase degree of the atopic dermatitis model mouse, and the fact that the corydalis tuber extract can be used for treating the atopic dermatitis is determined.
Drawings
FIG. 1 is a graph showing the results of inhibition of calcipotriol-induced damage to the skin epidermis barrier of mice by corydalis tuber extract;
FIG. 2 is a graph showing the results of inhibition of calcipotriol-induced weight loss in mice by corydalis tuber extract;
FIG. 3 is a graph showing the results of inhibition of calcipotriol-induced mouse scratch count by corydalis tuber extract;
FIG. 4 is a graph showing the results of inhibition of calcipotriol-induced increase in ear thickness in mice by corydalis tuber extract.
Detailed Description
In order that those skilled in the art will better understand the present invention, a technical solution in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings in which it is apparent that the described embodiments are only some embodiments of the present invention, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the present invention without making any inventive effort, shall fall within the scope of the present invention.
EXAMPLE 1 preparation of corydalis tuber extract
30g of vinegar corydalis tuber (purchased from Ningxia Minde Chinese medicinal decoction pieces Co., ltd.) is prepared, crushed into fine powder, added with 60% ethanol in an amount of eight times, heated and refluxed for 3 hours, the extract is collected, added with 60% ethanol in an amount of six times, heated and refluxed for 2 hours, the extract is collected, the secondary extract is combined, filtered, and the filtrate is concentrated until no alcohol smell exists.
The content measuring method of rhizoma corydalis is carried in China pharmacopoeia of 2015 edition, which uses tetrahydropalmatine as index component, and adopts high performance liquid chromatography to measure rhizoma corydalis extract, and the content of tetrahydropalmatine in rhizoma corydalis extract is 80ug/mL.
EXAMPLE 2 preparation of corydalis extract gel
Taking 30% poloxamer P407 6.67g, 45% poloxamer P188 1g and H 2 Mixing O2.33 g uniformly to obtain gel matrix, mixing rhizoma corydalis extract and gel matrix according to a mass ratio of 1:9 to obtain rhizoma corydalis extract gel with crude drug content of 0.25g/mL, and centrifuging at 5000r for 5 min to obtain rhizoma corydalis extract gel.
The invention also can prepare the corydalis tuber extract into ointment, cream, powder, aqua or lotion.
Example 3 corydalis tuber extract inhibits the symptoms of calcipotriol-induced atopic dermatitis in mice
1. Experimental materials
Corydalis tuber extract, calcipotriol (purchased from MCE company), 6-8 week old female C57 mouse (purchased from Xian university of transportation laboratory animal center)
2. Experimental method
Mice were divided into NC group (blank control group), vehicle group (negative control group), positive control group and rhizoma corydalis extract administration group. NC groups were not dosed. For the Vehicle group, calcipotriol (MC 903) was dissolved with ethanol, and then 20uL was applied to both sides of each ear of each mouse for 22 days. For the positive control group, calcipotriol was dissolved with ethanol, 20uL was applied to both sides of each ear of each mouse, and the application was continued for 22 days, and glucocorticoids were applied to the ears daily from day 13. For the rhizoma corydalis extract administration group, calcipotriol was dissolved in ethanol, 20uL was applied to both sides of each ear of each mouse, and the application was continued for 22 days, and the rhizoma corydalis extract (0.25 g/mL) prepared by applying gel matrix to the ear every day from day 13, counting the number of ear scratches within 10min on day 22, observing ear scales, and killing, and taking ear tissues.
3. Experimental results
As shown in fig. 1, calcipotriol smeared on ears caused the mice to scratch and damage the skin epidermis barrier, and scales increased compared to NC group. After the corydalis tuber extract is smeared on the ears of the mice, the damage of the skin epidermis barrier caused by the scratch of the mice caused by calcipotriol can be effectively inhibited, and the ear scales are reduced. After the ear of the mouse is smeared with the positive glucocorticoid, the damage of the skin epidermis barrier is inhibited, but the ear of the mouse is shrunken, namely adverse reaction is generated; the rhizoma corydalis extract did not cause ear shrinkage compared to the positive drug.
As shown in fig. 2, calcipotriol applied to the ears of mice caused weight loss in mice compared to NC group. The weight reduction degree of the glucocorticoid which is a positive medicament is further increased, which proves that the glucocorticoid which is a positive medicament has a certain toxicity to mice, and the rhizoma corydalis extract is not further reduced after being applied to the ears of the mice, which proves that the rhizoma corydalis extract has no toxicity to the mice.
As shown in fig. 3, application of calcipotriol to the ears of mice resulted in an increase in the number of scratches in mice, i.e., an increase in the content of the skin itch medium, compared to NC group. After the corydalis extract is applied to the ears of the mice, the scratching times of the mice are reduced, which indicates that the corydalis extract can effectively inhibit the increase of the content of the skin itch medium caused by calcipotriol.
As shown in fig. 4, calcipotriol applied to the ear caused an increase in the thickness of the mouse ear, i.e., an increase in the skin epidermal inflammatory factor content, compared to NC group. After the rhizoma corydalis extract is smeared on the ears of the mice, the thickness of the ears of the mice is obviously reduced, which indicates that the rhizoma corydalis extract can effectively inhibit the rise of the skin epidermis inflammatory factor content.
From a combination of figures 1-4, it can be seen that application of calcipotriol to the ears of mice causes significant atopic dermatitis symptoms in mice, including scratching times, body weight loss, skin epidermal barrier damage and elevated skin epidermal inflammatory factor levels. The rhizoma corydalis extract applied to mice by ear coating can effectively inhibit skin epidermis barrier damage, scratching times, release of skin itch medium and release of skin epidermis inflammatory factor, and relieve atopic dermatitis symptom of mice. The rhizoma corydalis extract can significantly improve the symptom of the atopic dermatitis of the mice, and the toxicity is lower than that of the glucocorticoid medicines commonly used in clinic.
In order to illustrate the technical idea of the present invention, the protection scope of the present invention is not limited by this, and any modification made on the basis of the technical scheme according to the technical idea of the present invention falls within the protection scope of the claims of the present invention.
Claims (9)
1. Application of rhizoma corydalis extract in preparing medicine for treating atopic dermatitis is provided.
2. The use according to claim 1, wherein the medicament is a medicament for inhibiting damage to the epidermal barrier of the skin.
3. The use according to claim 1, wherein the medicament is a medicament for inhibiting skin scale production.
4. The use according to claim 1, wherein the medicament is a medicament for inhibiting the release of a skin itch medium.
5. The use according to claim 1, wherein the medicament is a medicament for inhibiting the release of inflammatory factors of the epidermis of the skin.
6. The use according to claim 1, wherein the preparation method of the corydalis tuber extract comprises the following steps: pulverizing rhizoma corydalis, adding ethanol solution, heating under reflux, collecting extractive solution, filtering, and concentrating the filtrate.
7. A medicament for treating atopic dermatitis, characterized in that the medicament comprises a corydalis tuber extract.
8. The medicament for treating atopic dermatitis as claimed in claim 7, wherein the medicament is in the form of gel, ointment, cream, powder, aqueous or lotion.
9. The medicament for treating atopic dermatitis as claimed in claim 8, wherein the concentration of the corydalis tuber extract in the medicament is 0.1-0.4g/mL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311315432.7A CN117137965A (en) | 2023-10-11 | 2023-10-11 | Application of rhizoma corydalis extract in preparation of medicine for treating atopic dermatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311315432.7A CN117137965A (en) | 2023-10-11 | 2023-10-11 | Application of rhizoma corydalis extract in preparation of medicine for treating atopic dermatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117137965A true CN117137965A (en) | 2023-12-01 |
Family
ID=88902781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311315432.7A Pending CN117137965A (en) | 2023-10-11 | 2023-10-11 | Application of rhizoma corydalis extract in preparation of medicine for treating atopic dermatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117137965A (en) |
-
2023
- 2023-10-11 CN CN202311315432.7A patent/CN117137965A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109431943B (en) | Repairing paste for infantile eczema and preparation thereof | |
| JP4613012B2 (en) | The use of Jacobic whole coumarins in the preparation of a medicament for the treatment of psoriasis | |
| Zorko et al. | Efficacy of a polyphenolic extract from silver fir (Abies alba) bark on psoriasis: A randomised, double-blind, placebo-controlled trial | |
| KR101734093B1 (en) | A pharmaceutical composition for preventing and treating inflammatory disease containing the purified bee venom which was reduced allergen, as a active ingredient | |
| CN117137965A (en) | Application of rhizoma corydalis extract in preparation of medicine for treating atopic dermatitis | |
| CN114209756B (en) | Anti-inflammatory and antipruritic traditional Chinese medicine composition and preparation method and application thereof | |
| CN114732863A (en) | Traditional Chinese medicine composition for treating nephropathy and application thereof | |
| CN115444917B (en) | Traditional Chinese medicine composition and traditional Chinese medicine cream for treating eczema, and preparation methods and application thereof | |
| CN116850236B (en) | Externally-applied traditional Chinese medicine composition for treating psoriasis as well as preparation and application thereof | |
| CN1308019C (en) | Chinese medicinal composition for treating chronic pelvic inflammation and preparation method thereof | |
| CN117100790A (en) | Application of rhizoma corydalis-radix angelicae extract in preparation of anti-atopic dermatitis medicine | |
| CN110624081A (en) | Traditional Chinese medicine composition for treating goiter and preparation method thereof | |
| CN116585397B (en) | Pharmaceutical composition for treating eczema and preparation method and application thereof | |
| CN116898904B (en) | Application of radix scutellariae and radix paeoniae rubra composition in preparing medicines for preventing and/or treating atopic dermatitis | |
| CN115645502B (en) | Medicament for treating infant eczema | |
| CN117899098B (en) | Application of rare ginsenoside CMx in preparation of medicine for preventing and/or treating type 2 inflammatory diseases | |
| CN115554330B (en) | Entada phaseoloides extract for resisting inflammation and relieving itching, and preparation method and application thereof | |
| CN113893287B (en) | External traditional Chinese medicine preparation for treating eczema | |
| CN114848761B (en) | Traditional Chinese medicine composition for treating children eczema and preparation method and application thereof | |
| CN114366732B (en) | Application of tiamulin in preparation of medicine for treating psoriasis | |
| KR20120057161A (en) | Pharmaceutical Composite Comprising Tortoise/Turtle For Improvement or Treatment of Skin Disease | |
| CN115844940A (en) | Composition and paste for treating cervicitis and preparation method thereof | |
| CN108114029A (en) | A kind of active Chinese drug component compositions, its preparation method and its application | |
| CN118903284A (en) | Traditional Chinese medicine composition for treating radiation intestinal injury and application thereof | |
| CN118615340A (en) | Use of extract of apices Apii for preventing or treating liver diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |